Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 3Endocrine 3Gastrointestinal 1CNS 1

Conditions

Neuroendocrine Tumors 6Meningioma 6Paraganglioma 5Neuroblastoma 5Pheochromocytoma 4Medulloblastoma 3Carcinoid Tumor 2von Hippel-Lindau Disease 1Somatostatinoma 1Pinealoma 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroma, Acoustic 1Neuroectodermal Tumors, Primitive 1Neoplasms, Neuroepithelial 1Multiple Endocrine Neoplasia Type 1 1Kidney Neoplasms 1Hypertension 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ganglioneuroma 1Ganglioneuroblastoma 1Familial ependymoma 1Ependymoma 1Craniopharyngioma 1Choroid Plexus Neoplasms 1Brain Neoplasms 1

Interventions

belzutifan 2spartalizumab 1gallium Ga 68 dotatate 1Magnetic Resonance Spectroscopy 1Everolimus 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
von Hippel-Lindau Disease × gallium Ga 68 dotatate × CNS × Clear all
NCT03001349 2021-02-15

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Terminated
4 enrolled
CNSEndocrineNET

von Hippel-Lindau Disease, Meningioma, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡